Insider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 5,000 Shares of Stock

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total transaction of $333,850.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at $3,133,916.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Edwards Lifesciences Trading Up 0.6 %

NYSE EW opened at $68.52 on Friday. The stock has a market cap of $41.28 billion, a P/E ratio of 29.53, a P/E/G ratio of 2.85 and a beta of 1.13. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a fifty day simple moving average of $72.39 and a two-hundred day simple moving average of $83.49.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. During the same quarter in the previous year, the business earned $0.66 EPS. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. On average, analysts forecast that Edwards Lifesciences Co. will post 2.7 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Barclays reduced their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. UBS Group cut their target price on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Tuesday. The Goldman Sachs Group lowered their price target on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Bank of America lowered shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $105.00 to $75.00 in a research note on Thursday, July 25th. Finally, Citigroup increased their target price on shares of Edwards Lifesciences from $105.00 to $106.00 and gave the company a “buy” rating in a research note on Wednesday, July 10th. Fifteen analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $80.29.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EW. DSM Capital Partners LLC purchased a new position in Edwards Lifesciences during the fourth quarter worth about $28,000. Crewe Advisors LLC purchased a new position in Edwards Lifesciences during the 1st quarter valued at about $28,000. First Community Trust NA acquired a new position in Edwards Lifesciences in the 2nd quarter valued at about $29,000. Riverview Trust Co purchased a new stake in Edwards Lifesciences during the first quarter worth about $34,000. Finally, Pingora Partners LLC acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $38,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.